Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest digestive disease Stories

2009-09-09 06:00:00

SAN DIEGO, Sept. 9 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it is providing a co-pay assistance savings program for LOTRONEX(R) (alosteron HCl) patients. The savings program is available through physicians enrolled in the Prescribing Program for Lotronex(TM) and local pharmacies. Patients are responsible for the first $50 of their LOTRONEX prescription co-pay, after which they are eligible to receive a savings of...

2009-09-08 06:00:00

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will...

2009-08-19 09:50:00

High-dose ursodeoxycholic acid associated with worsened disease state for patients with PSCPrimary sclerosing cholangitis (PSC) is an uncommon chronic liver disease characterized by progressive inflammation and destruction of the bile ducts. The disease progresses slowly, usually leading to biliary cirrhosis, portal hypertension and liver failure over a 10-15 year period. PSC is a common cause of adult cholestatic liver diseases and a primary source behind many of the liver transplantations...

2009-05-12 07:00:00

- Data to be presented at Digestive Disease Week 2009 - CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be reporting additional clinical data from their Phase 2b studies for linaclotide, a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), during the 2009 Digestive Disease Week...

2009-03-16 06:00:00

SAN DIEGO, March 16 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has received New York State approval for PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). This novel test incorporates 10 biomarkers, two of which are proprietary, along with a proprietary algorithm to help physicians diagnose patients with IBS. "One out of five Americans has symptoms of IBS, however the...

2008-11-05 18:00:23

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the third quarter ended September 30, 2008. Total product revenue was $42.9 million for the third quarter of 2008, compared to $67.4 million for the third quarter of 2007. Total product revenue for the first nine months of 2008 was $118.2 million compared to $193.8 million for the first nine months of 2007. The decrease in total product revenue for the quarter and nine months was due to the...

2008-10-06 12:00:12

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- Ironwood Pharmaceuticals (formerly Microbia) today announced presentation of data from a pair of preclinical studies delineating the role that cyclic guanosine monophosphate (cGMP) plays in alleviating intestinal pain. These studies demonstrate that cGMP inhibits intestinal pain in a preclinical model of intestinal hyperalgesia and desensitizes colonic afferent nerves in a similar model of experimental colitis. These results are from separate, ongoing...

2008-10-01 12:00:07

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced it has raised $50 million in a private equity financing. This capital will be utilized to support the ongoing Phase 3 development program evaluating linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), to invest in a growing pipeline of internally discovered drug candidates, and to expand commercial capabilities. The financing was led by Morgan...

2008-06-17 06:00:07

Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development. It is a potent prokinetic agent initially being developed for the treatment of mild-to-moderate gastroparesis. The Phase I study showed that TZP-102 has excellent oral bioavailability in man and is safe and...

2007-01-14 03:00:08

By Mino-Kenudson, Mari; Tomita, Shigeki; Lauwers, Gregory Y * Context.-Reactive gastropathy is the second most common diagnosis made on gastric biopsies. Increased epithelial proliferation and modifications of epithelial cytokeratin profile, distinct from those of Helicobacter pylori gastritis, have been previously reported. However, the evaluation of mucins, important components of the protective mucosal mucous layer, has not been reported. Objective.-To investigate alterations of...